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Abstract
Background: Although cis-diamminedichloro-platinum (CDDP) exhibits strong therapeutic effects in cancer
chemotherapy, its adverse effects such as peripheral neuropathy, nephropathy, and vomiting are dose-limiting
factors. Previous studies reported that chronotherapy decreased CDDP-induced nephropathy and vomiting. In
the present study, we investigated the influence of dosing times on CDDP-induced peripheral neuropathy in rats.
Methods: CDDP (4 mg/kg) was administered intravenously at 5:00 or 17:00 every 7 days for 4 weeks to male
Sprague–Dawley rats, and saline was given to the control group. To assess the dosing time dependency of
peripheral neuropathy, von-Frey test and hot-plate test were performed.
Results: In order to estimate hypoalgesia, the hot-plate test was performed in rats administered CDDP weekly
for 4 weeks. On day 28, the withdrawal latency to thermal stimulation was significantly prolonged in the
17:00-treated group than in the control and 5:00-treated groups. When the von-Frey test was performed to
assess mechanical allodynia, the withdrawal threshold was significantly lower in the 5:00 and 17:00-treated
groups than in the control group on day 6 after the first CDDP dose. The 5:00-treated group maintained
allodynia throughout the experiment with the repeated administration of CDDP, whereas the 17:00-treated
group deteriorated from allodynia to hypoalgesia.
Conclusions: It was revealed that the severe of CDDP-induced peripheral neuropathy was inhibited in the 5:00-treated
group, whereas CDDP-treated groups exhibited mechanical allodynia. These results suggested that the selection of an
optimal dosing time ameliorated CDDP-induced peripheral neuropathy.
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Background
Cisplatin, cis-diamminedichloro-platinum (CDDP), is the
first agent of platinum-based anticancer drugs, and acts by
crosslinking DNA and inhibiting DNA replication [1, 2]. It
is extensively used in the treatment of non-small cell lung,
head and neck, ovarian, and breast cancers [3–6], and
exhibits strong therapeutic effects in cancer chemother-
apy. Although CDDP is the main drug used in chemother-
apy, it has dose-limiting adverse effects such as peripheral
neuropathy, nephropathy, and vomiting, which limit the
continuation of chemotherapy [7–9]. As a counter-
measure to CDDP-induced adverse effects, fluid ther-
apy and diuretic drugs have been used for nephropathy
[10, 11]. Serotonin 3 receptor antagonists and neurokinin-
1 receptor antagonists have also been administered to pre-
vent vomiting [12–16]. However, no effective treatment
currently exists for peripheral neuropathy [17–20].
CDDP-induced peripheral neuropathy frequently occurs
in patients receiving CDDP at a total dose of more than
300 mg/m2 [21]. Patients with CDDP-induced peripheral
neuropathy have difficulty moving their arms, feet, and fin-
gers as well as difficulty walking, numbness, dysesthesia,
sensory abnormalities, and autonomic neuropathy [21–23].
The chronic symptoms of CDDP-induced neuropathy,
which may continue for months after the cessation of
treatment, may be due to the accumulation of platinum
compounds in the dorsal root ganglia (DRG) [24, 25].
The quality of life (QOL) of patients with these symp-
toms is reduced and these adverse effects also limit the
continuation of chemotherapy. Therefore, the prevention
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or suppressing of CDDP-induced peripheral neuropathy
is desired.
The success of chronotherapy in ameliorating adverse
effects and achieving improved therapeutic effects has
been attributed to a deeper understanding of pathological
characteristics and pharmacological characterization as
well as the selection of an optimal dosing time for drug
administration [26, 27]. Previous studies reported that
chronotherapy was beneficial for the adverse effects of
CDDP. Nephropathy was ameliorated when CDDP was
administered in the active phase of these animals [28–31].
Moreover, vomiting induced by CDDP improved in pa-
tients with urogenital cancer when CDDP was adminis-
tered at 17:00 [32]. Thus, chronotherapy may ameliorate
CDDP-induced peripheral neuropathy.
In the present study, we investigated the influence of
dosing times on CDDP-induced peripheral neuropathy
in rats, and the pharmacokinetics of CDDP in serum
and the DRGs in order to elucidate the mechanisms
responsible for dosing time-dependent differences.
Methods
Animals
Male Sprague–Dawley (SD) rats (6 weeks old) were pur-
chased from Japan SLC, Ltd. (Japan). Rats were housed
two to three per cage under standardized light–dark
cycle conditions (lights on and off at 7:00 and 19:00,
respectively) at a room temperature of 23–25 °C and
humidity of 50– 60 % with free access to food and water.
All rats were kept under these conditions for 1 week
until used in experiments, and the body weights were
220–260 g at point of starting experiments. Experiments
were performed after formal approval by the Committee
for Animal Experiments at the University of Toyama.
Preparation of CDDP
CDDP, supplied by Nippon Kayaku Co., Ltd. (Tokyo,
Japan), was dissolved in saline. Its final concentration
was 2 mg/mL (4 mg/kg) in each dosing group. CDDP
was intravenously (i.v.) administered at 2 mL/kg to rats.
Experiment I: Influence of CDDP administration on
peripheral neuropathy
CDDP was administered i.v. at 17:00 every 7 days for
4 weeks to rats (n = 4 in Hot plate test, n = 8 in von-Frey
test). Saline was given to the control group (n = 4 in Hot
plate test, n = 8 in von-Frey test).
The withdrawal threshold was measured on days −1,
6, 13, 20, and 27 using the von-Frey test during the
administration of CDDP. Withdrawal latency by heat
stimulation was determined on days −1, 6, and 27 using
the hot-plate test during the administration of CDDP.
Experiment II: Influence of CDDP dosing times on adverse
effects
CDDP was administered i.v. at 5:00 or 17:00 every 7 days
for 4 weeks (n = 10). Saline was given to the control
group (n = 6–12). Body weights were recorded on days
0, 7, 14, 21, and 28 after the first administration of
CDDP. Change rates in body weights were calculated as
percent body weight change in each rat from the initial
value (day 0).
Blood samples were obtained from the tail vein 5, 12,
19, and 26 days after the administration of CDDP in
order to measure blood urea nitrogen (BUN) concentra-
tions. All blood samples were immediately centrifuged at
3000 × g for 10 min at 15 °C, and serum was then frozen
at −80 °C until assays were performed. BUN concentra-
tions were measured using a manufactured kit (Wako
Pure Chemical Industries, Ltd., Japan).
Experiment III: Influence of CDDP dosing times on
recovery from mechanical allodynia after the single
administration of CDDP
CDDP was administered i.v. at 5:00 or 17:00 (n = 8), and
saline was given to the control group (n = 8). The von--
Frey test was performed on days −7, −5, −3, −1, 1, 2, 3,
6, 10, 13, 17, and 20 before and after the initial
administration of CDDP to measure the paw withdrawal
threshold. The hot-plate test was performed on day 24
after the administration of CDDP to measure withdrawal
latency by heat stimulation.
Experiment IV: Influence of CDDP dosing times on
peripheral neuropathy during its repeated administration
CDDP was administered i.v. at 5:00 or 17:00 every 7 days
for 4 weeks (n = 4–10). Saline was given to the control
group (n = 4–12). The von-Frey test was performed on
days −7, −5, −3, −1, 3, 6, 10, 13, 17, 20, 24, and 27 before
and after the initial administration of CDDP to measure
the paw withdrawal threshold. The hot-plate test was
performed on days 6 and 28 after the administration of
CDDP to measure withdrawal latency by heat stimulation.
Experiment V: Chronopharmacokinetics of CDDP
CDDP was administered i.v. at 5:00 or 17:00 every 7 days
for 4 weeks (n = 6). Blood samples were obtained from
the tail vein at 5, 15, 30, 60, 120, 240, 360, 480, and
720 min after the first and fourth administration of
CDDP. All blood samples were centrifuged immediately
at 3000 × g for 10 min at 15 °C. Lumber 4 (L4), L5, and
L6 DRG samples were isolated from each anesthetized
rats at 24 h after the first and fourth administration of
CDDP. Serum and DRG samples were frozen at −80 °C
until analyzed.
In order to determine serum CDDP concentrations,
10 μL of rat serum was mixed with 990 μL of 60 %
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HNO3, with Indium ICP-MS standard (Wako Pure
chemical Industries, Ltd.) as an internal standard. Each
DRG was mixed with 2000 μL of 60 % HNO3, with
Indium ICP-MS standard as an internal standard, to
determine total CDDP concentrations in DRG. This
solution was incubated at 100 °C for 30 min, and then
diluted 100 times with ultrapure water.
Total platinum concentrations were assayed using
inductively coupled plasma mass spectrometry on an
ELEMENT2™ ICP-MS (Thermo Fisher Scientific, Inc.).
The operating parameters of the ICP-MS instrument
were as follows: RF power 1280 W, cool gas flow
15.58 L/min, auxiliary gas flow 0.80 L/min, sample gas
flow 0.98 L/min, dead time 25 ns, take-up time 1 min,
and four replicates per sample.
von-Frey test
We used the method of previous report [33]. Mechanical
allodynia was assessed using a Touch-test sensory eva-
luater (Muromachi Kikai Co., Ltd., Japan) at 12:30–13:30
on each measuring day. Each rat was placed in a plastic
cage with a wire mesh floor and allowed to acclimate for
10 min before measuring hind paw mechanical thresh-
olds. Filaments, with bending forces that ranged from 1
to 180 g, were applied to the middle of the plantar
surface of the right hind paw and held for 5 sec. The
withdrawal threshold of the right hind paw was deter-
mined by increasing the stimulus strength from the 1 g
filament until paw withdrawal occurred.
Hot-plate test
Thermal hyperalgesia and hypoalgesia were assessed
using a hot plate analgesia meter (Muromachi Kikai
Co., Ltd., Japan) at 12:30–13:30 on each measuring day.
Each rat was placed in a plastic cage with a wire mesh
floor and allowed to acclimate for 10 min before measuring
hind paw thermal thresholds. A hot plate was pre-heated
and maintained at a temperature of 50 ± 0.5 °C. The time
for the first sign of nociception, paw licking, flinching, or a
jumping response to avoid the heat was recorded. A cut-off
period of 60 sec was maintained to avoid damage to the
hind paws [34].
Statistical analysis
All values were shown as a mean with standard error of the
mean (S.E.M.). A one-way analysis of variance (ANOVA)
was used for multiple comparisons, and Scheffe’s test was
used for comparisons between two groups. The Stu-
dent’s t-test was used for comparisons between two groups.
P values of less than 0.05 were considered significant.
Results
Influence the repeated administration of CDDP on
peripheral neuropathy
On day 6, the paw withdrawal threshold in the von-Frey
test and the withdrawal latency in the hot-plate test were
significantly lower in the CDDP-treated group than in
the control group (P < 0.01, respectively, Table 1). On
other days, no significant differences were observed in
the paw withdrawal thresholds between the control and
CDDP-treated groups. Withdrawal latency was signifi-
cantly longer in the CDDP-treated group than in the
control group on day 27 (P < 0.05).
Influence of CDDP dosing times on body weights and
BUN
Body weights were significantly lower in the CDDP-
treated groups than in the control group throughout this
study (P < 0.01, respectively, Fig. 1a). Decreases in
change rates in body weights were significantly better in
the 5:00-treated group than in the 17:00-treated group
at all points measured (P < 0.05 or P < 0.01, respectively).
When CDDP was administered every 7 days, BUN
levels in the CDDP-treated groups over time were higher
than the control levels (Fig. 1b). Increases in BUN con-
centrations were significantly lower in the 5:00-treated
group than in the 17:00-treated group on days 5, 19, and
26 (P < 0.05 or P < 0.01, respectively).
Influence of CDDP dosing times on recovery from
mechanical allodynia after single administration
On days 6, 10, and 13 after the single administration of
CDDP, paw withdrawal thresholds in the CDDP-treated
groups were significantly lower than those in the control
group (P < 0.05 and P < 0.01, respectively, Fig. 2a). The
17:00-treated group continued to maintain mechanical
allodynia for 20 days, and paw withdrawal thresholds
Table 1 Time courses of paw withdrawal thresholds and withdrawal latency during the weekly administration of CDDP to rats
Behavioral test Groups Time before/after the first administration (days)
−1 6 13 20 27
von-Frey test Control 51.5 ± 5.6 g 51.5 ± 5.6 g 47.3 ± 6.2 g 45.9 ± 7.0 g 51.5 ± 5.6 g
CDDP 55.8 ± 4.3 g 15.9 ± 2.4 g** 40.3 ± 7.6 g 56.5 ± 8.3 g 70.8 ± 9.5 g
Hot-plate test Control 15.9 ± 1.5 sec 14.5 ± 0.4 sec - - 14.4 ± 1.4 sec
CDDP 14.4 ± 1.8 sec 9.7 ± 0.9 sec** - - 37.1 ± 7.3 sec*
Each data represent the mean with S.E.M. in the von-Frey test (n = 8) and in the hot-plate test (n = 4), *: P < 0.05, and **: P < 0.01 using the Student’s t-test
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Fig. 1 Influence of CDDP dosing times on adverse effects (a Change rate in body weight, b BUN) in rats. CDDP was administered every 7 days at
5:00 or 17:00. Saline was administered to the control group. Each value represents the mean with S.E.M. (a control group (n = 12); each CDDP-treated
group (n = 10). b each control group (n = 6); each CDDP-treated group (n = 10)). a **: P < 0.01 versus the control group; #: P < 0.05 and ##: P < 0.01
versus the 5:00-treated group using Scheffe’s test. b *: P < 0.05 and **: P < 0.01 versus the control group at 5:00; #: P < 0.05 and ##: P < 0.01











































Fig. 2 Influence of CDDP dosing times on recovery from mechanical allodynia in rats after a single dose (a von-Frey test, b Hot plate test on
day 24). CDDP was administered to rats at 5:00 or 17:00. Saline was administered to the control group. Each value represents the mean with S.E.M.
(n = 8). *: P < 0.05, **: P < 0.01 versus the control group; #: P < 0.05 versus the 5:00-treated group using Scheffe’s test
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were significantly lower than those in the control group
(P < 0.05 and P < 0.01, respectively). On the other hand,
the paw withdrawal threshold in the 5:00-treated group
increased with the passage of time from 10 days after
the administration of CDDP. Although paw withdrawal
thresholds were significantly higher in the 5:00-treated
group than in the 17:00-treated group on days 17, and
20 (P < 0.05, respectively), no significant differences were
observed between the control and 5:00-treated groups
on days 17 and 20.
On day 24, no significant differences were noted in
the withdrawal latency by heat stimulation among any
groups (Fig. 2b).
Influence of CDDP dosing times on paw withdrawal
thresholds during repeated administration
Paw withdrawal thresholds in the 5:00-treated group
markedly decreased from normal levels after the first
administration of CDDP, and were maintained at low
levels throughout the experiment (Fig. 3). Paw with-
drawal thresholds were significantly lower in the 5:00-
treated group than in the control group throughout this
study (P < 0.01, respectively). On the other hand, the
17:00-treated group showed temporary decreases in
paw withdrawal thresholds, which were significantly
lower than those in the control and 5:00-treated groups
on day 6 (P < 0.01). Paw withdrawal thresholds in the
17:00-treated group increased after the second adminis-
tration of CDDP (day 7), and were similar to those in
the control group by day 17. On day 27, paw with-
drawal thresholds were significantly higher in the
17:00-treated group than in the control group (P <
0.01). Paw withdrawal threshold were significantly
lower in the 5:00-treated group than in the 17:00-
treated group from day 10 to 27 (P < 0.01, respectively).
Influence of CDDP dosing times on hypoalgesia during
repeated administration
No significant differences were observed in the with-
drawal latency by heat stimulation among any groups on
day 6 after the first administration of CDDP (Fig. 4a).
On day 28, the withdrawal latency was significantly
higher in the 17:00-treated group than in the control
and 5:00-treated groups after the fourth administration
of CDDP (P < 0.01, respectively, Fig. 4b). On the other
hand, no significant differences were observed in the
withdrawal latency between the control and 5:00-
treated groups.
Influence of CDDP dosing times on pharmacokinetics in
serum and dorsal root ganglia (DRG)
No significant differences in CDDP concentrations were
observed in serum between the 5:00 and 17:00-treated
groups after the first administration of CDDP (Table 2).
Serum concentrations were significantly lower in the
5:00-treated group than in the 17:00-treated group 60,
120, 240, 360, and 720 min after the fourth administra-
tion of CDDP (P < 0.05 and P < 0.01, respectively).
No significant differences were observed in CDDP con-
centrations in DRG between the 5:00 and 17:00-treated
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Fig. 3 Influence of CDDP dosing times on withdrawal thresholds during its administration to rats. CDDP was administered every 7 days at 5:00 or
17:00. Saline was administered to the control group. Each value represents the mean with S.E.M. (n = 8). **: P < 0.01 versus the control group;
##: P < 0.01 versus the 5:00-treated group using Scheffe’s test
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Discussion
CDDP-induced peripheral neuropathy is a dose-limiting
factor [7]. Although previous studies have attempted to
prevent and decrease peripheral neuropathy, effective
treatments have not yet been developed [17–20]. CDDP-
induced peripheral neuropathy exhibits contrary pain
reactions, such as allodynia and hypoalgesia [21–23]. In
the early stage, neuropathy appears as allodynia, which
is pain induced by a nonnoxious stimulus, and gradually
progresses to hypoalgesia, namely, a decrease or the dis-
appearance of sensations by nonnoxious and noxious
stimuli, when CDDP is continuously administered [23, 35].
However, it was not reported that an animal model of the
CDDP-induced peripheral neuropathy matched clinical
situation. Then, at the first, we studied to make the model.
When CDDP (4 mg/kg) was given i.v. once weekly, rats
showed mechanical allodynia on day 6 after the first ad-
ministration and prolonged the withdrawal latency by heat
stimuli on 6 days (day 27) after the last dose (Table 1). The
acute response concerned with the result in mice treated
CDDP (2.3 mg/kg) in the past report [36]. This observation
that the peripheral neuropathy caused by CDDP gradually
progressed to hypoalgesia during the continuous adminis-
tration, mirrors previous work in rats by Han FY et al. [37].
It was thought that this change in symptom of peripheral
neuropathy may reflect the clinical situation.
Peripheral neuropathy induced by oxaliplatin was pre-
viously shown to be ameliorated by chronotherapy in
patients with measurable metastases from colorectal
cancer [38]. Moreover, the chronopharmacology of
CDDP had shown many evidences in animal and hu-
man [29, 31, 32]. In animal studies, the toxicities such
as nephrotoxicity and toxic death were the highest at
rest phase in a day. Therefore, we selected the two dos-
ing times (5:00 and 17:00) by referring these reports. In
the present study, the group treated with CDDP at rest
phase (17:00) showed severe toxicities compared with










































Fig. 4 Influence of CDDP dosing times on hypoalgesia during its repeated administration to rats. CDDP was administered every 7 days at 5:00 or
17:00. Saline was administered to the control group. Each value represents the mean with S.E.M. a (n = 4); b (n = 8). P < 0.01 using Scheffe’s test
Table 2 Influence of dosing time on serum CDDP concentrations after the first or fourth administration of CDDP to rats
Groups CDDP concentration (μg/mL)
5 min 15 min 30 min 60 min 120 min 240 min 360 min 480 min 720 min
The first administration
5:00 4.62 ± 0.49 3.58 ± 0.17 1.90 ± 0.13 0.87 ± 0.07 0.72 ± 0.03 0.65 ± 0.05 0.63 ± 0.02 0.60 ± 0.01 0.52 ± 0.02
17:00 4.84 ± 0.44 3.68 ± 0.26 1.93 ± 0.15 0.86 ± 0.05 0.71 ± 0.06 0.66 ± 0.04 0.61 ± 0.03 0.57 ± 0.03 0.52 ± 0.05
The fourth administration
5:00 6.75 ± 0.59 5.34 ± 0.27 3.79 ± 0.20 2.71 ± 0.20 1.74 ± 0.10 1.52 ± 0.13 1.34 ± 0.11 1.12 ± 0.09 1.12 ± 0.04
17:00 7.38 ± 0.24 5.13 ± 0.21 3.81 ± 0.10 2.14 ± 0.09* 1.32 ± 0.05** 1.16 ± 0.06* 1.03 ± 0.07* 0.97 ± 0.06 0.89 ± 0.04**
Each value represents the mean with S.E.M. (n = 6), *: P < 0.05, and **: P < 0.01 using the Student’s t-test
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differences in adverse effects were consistent with
previous findings [28–31]. In the present study, the
17:00-treated group showed 73.9 mg/dL of BUN level
on day 19 and 55.8 g of withdrawal threshold on day 20
when CDDP was weekly given. On the other hands,
withdrawal threshold in the 5:00-treated group, in
which BUN level showed 82.4 mg/dL on day 26, was
5.3 g on day 27. There is no correlation between degree
of the nephrotoxicity and the neuropathy. Therefore,
we considered that the dosing-time dependency of se-
verity of neuropathy did not necessarily coincide with
the CDDP-related toxicities.
The CDDP-treated groups showed significantly lower
withdrawal thresholds than the control group immedi-
ately after administration of CDDP. However, mechan-
ical allodynia was temporary in the 5:00-treated group
after a single administration and the 17:00-treated
group when CDDP was given once weekly. The both
dosing groups showed exactly the opposite response
against mechanical allodynia by the difference in the
number of doses. The reason is thought two possible.
The neuropathy was improved by repair factor. Or the
rats stopped responding to stimuli by progressing hypoal-
gesia. After a single administration of CDDP, there were
no significant differences to heat stimulation among the
all groups on day 24. On the other hand, the withdrawal
latency was approximately 2-fold longer in the 17:00-
treated group than in the control and 5:00-treated groups
on day 28 after the repeated administration. Because the
increase in withdrawal latency shows the onset of hypoal-
gesia, increase in withdrawal thresholds after the single
dose may indicate recovery from mechanical allodynia in
the 5:00-treated group. In the present study, peripheral
neuropathy in the 17:00-treated group progressed from
allodynia to hypoalgesia, similar to clinical situations [23].
The 5:00-treated group maintained allodynia while CDDP
was repeatedly administered. Animal studies previously
demonstrated that CDDP induced mechanical allodynia
after its administration, and recovery from mechanical
allodynia was observed after discontinuation of the
treatment [39, 40]. These results suggested that the
development of severe CDDP-induced peripheral neur-
opathy was delayed or inhibited in the 5:00-treated
group. Therefore, the selection of an optimal dosing-
time may lead to an effective approach for peripheral
neuropathy induced by CDDP.
A previous study reported that sensory nerve conduc-
tion velocity (SNCV) was decreased by CDDP-induced
peripheral neuropathy [41–43]. In order to clarify dos-
ing time-dependent differences in the phenotypes of
pain responses, the SNCV of the coccygeal nerve was
measured 7 days (day 28) after the fourth administra-
tion of CDDP. SNCV was markedly lower in the 17:00-
treated group than in the control and 5:00-treated
groups (Additional file 1). However, no nerve activity
against the electric stimulus was observed in some rats
treated with CDDP at 17:00, and thus, SNCV could not
be sufficiently calculated. Although it remains unclear
whether this result was due to a decline in the conduc-
tion velocity because of severe peripheral neuropathy
or a technical error, SNCV was markedly decreased in
the 17:00-treated group, which showed an increase in
a b
Fig. 5 Influence of CDDP dosing times on its concentration in the dorsal root ganglia (DRG) after its first (a) or fourth (b) administration. CDDP was
administered every 7 days at 5:00 or 17:00. Each value represents the mean with S.E.M. (n = 6)
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the withdrawal latency by the heat stimulation. These
responses were observed when the peripheral nerve
was injured. We then performed a pathological assess-
ment of the peripheral nerve in the 17:00-treated group
6 days (day 27) after the fourth administration of CDDP
in a preliminary study. No marked difference was noted
between the control and 17:00-treated groups (Additional
file 2). Gilardini A et al. reported that the absence of struc-
tural injuries with CDDP-induced peripheral neuropathy
[44]. These findings suggested that peripheral neuropathy
was more severe in the 17:00-treated group than in the
5:00-treated group; however, pathological assessments
could not clarify dosing time-dependent differences in
CDDP-induced peripheral neuropathy. Therefore, there
was no effective scale to assess histological changes in
peripheral nerves such as the sciatic nerve. We intend
to investigate genes and proteins related to pain.
The accumulation of CDDP in the DRGs, which con-
tain the cell bodies of primary afferent sensory neurons
and play a role in pain mechanisms, is known to induce
CDDP-induced peripheral neuropathy [25]. A previous
study reported that the enhanced accumulation of
CDDP in the DRG positively correlated with the sever-
ity of peripheral neuropathy in mice [45]. In the present
study, no significant differences were noted in the
DRGs levels of CDDP between the 5:00 and 17:00-
treated groups. In clinical study, there are few reports
of chronopharmacokinetics of CDDP. When CDDP was
given at 6:00 or 18:00, the clearance (CL) significantly
was higher at 18:00 than at 6:00 [46]. In this study,
serum CDDP concentrations were markedly lower in
the 17:00-treated group than the 5:00-treated group
60–720 min after the injection. It was consistent with
human and animal that disappearance of CDDP from
blood was faster in the active phase than the rest phase.
However, the toxicities were inhibited in the 5:00-
treated group showed higher the serum level. There-
fore, we thought that CDDP pharmacokinetics might
not contribute to the dosing time-dependent neur-
opathy. CDDP shows pharmacological effects by cross-
linking DNA. It was reported that platinum level in
DNA in kidney showed clear dosing time-dependent
difference, and the daily variation contributed to degree
of nephrotoxicity [47]. In this study, platinum concentra-
tion in DNA in DRG was not measured because DRG was
small tissue. We are studying measurement method of the
platinum level in DNA in nerve tissue including DRG to
clarify relevance between the dosing time-dependency of
neuropathy and the platinum level in DNA.
Although it is an important to estimate dosing time-
dependency of antitumor effect, we have not studied
the antitumor effects because LLC-WRC-256 cells, which
were breast carcinosarcoma in rat, cannot be transplanted
to SD rats. In the preliminary study, the 17:00-treated
group (late rest phase) was markedly lower in tumor
growth than the control group when CDDP (5 mg/kg)
was i.v. given in ICR nu/nu mice bearing A549 cells,
which is human lung cancer (Additional file 3). Oxalipla-
tin, which is the third generation platinum anticancer
drug, showed high tumor inhibition rate at early active
phase compared with late rest phase [48]. Optimal dosing-
time of antitumor effects differs by drugs, cancer cell, and
engraftment site. Unlike the side effects that target factors
are limited, it is difficult to select a uniform dosage timing
for target factor is the variety against cancer. Therefore,
we think that long-term CDDP therapy can be carried out
by decreasing adverse effects using chronotherapy and
anti-tumor effect would be directly or indirectly enhanced
as a result.
Conclusions
In conclusion, pain is an important sign to avoid a
variety of risk in life, and hypoalgesia induced by the
drug must be avoided. The present study revealed that
CDDP-induced peripheral neuropathy which proceeded
from allodynia to hypoalgesia was inhibited by the
administration of CDDP at a specific time. The adverse
effects of CDDP, body weights, BUN levels, and periph-
eral neuropathy may be improved by identical dosing
times. Thus, chronotherapy may contribute to ameliorat-
ing adverse effects in patients receiving chemotherapy
with CDDP.
Additional files
Additional file 1: Historogical change of sciatic nerve after the fourth
administration of CDDP. No significant differences were observed
between the control and 17:00-treated groups. (PPTX 271 kb)
Additional file 2: Influence of CDDP dosing times on SNCV after the
fourth administration of CDDP to rats on day 27. Each value represents
the mean with S.E.M. (n = 7–10). (PPTX 74 kb)
Additional file 3: Dosing-time dependent change in the antitumor
effect after CDDP 5 mg/kg i.v. every 7 days at 5:00 or 17:00 in A549
tumor bearing mice. ●: control group, □: CDDP 5:00 treated group,
■: CDDP 17:00 treated group, Arrows: CDDP administrations. Each value
represents the mean ± S.E.M. of 9 or 10 mice. **: P < 0.01 (Scheffe’s test).
The 17:00 treated group decreased the relative tumor growth
compared with the 5:00 treated group. (PPTX 355 kb)
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